Tempus AI (NASDAQ:TEM) Trading Down 14.5% on Insider Selling

Shares of Tempus AI, Inc. (NASDAQ:TEM) fell 14.5% on Thursday after an insider sold shares in the company. The company traded as low as $72.25 and last traded at $73.25. 12,344,723 shares changed hands during trading, a decline of 13% from the average session volume of 14,108,291 shares. The stock had previously closed at $85.71.

Specifically, CFO James William Rogers sold 31,780 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40. Following the sale, the chief financial officer now directly owns 189,320 shares of the company’s stock, valued at approximately $15,586,715.60. This represents a 14.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Erik Phelps sold 61,582 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $82.36, for a total transaction of $5,071,893.52. Following the sale, the executive vice president now directly owns 153,080 shares in the company, valued at $12,607,668.80. This trade represents a 28.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In related news, CAO Ryan M. Bartolucci sold 818 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total transaction of $66,969.66. Following the sale, the chief accounting officer now directly owns 46,182 shares of the company’s stock, valued at approximately $3,780,920.34. This represents a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. William Blair downgraded shares of Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Finally, TD Cowen reissued a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Stock Down 11.2 %

The business’s 50-day simple moving average is $50.29 and its two-hundred day simple moving average is $51.65. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Tempus AI during the fourth quarter valued at about $108,000. Voloridge Investment Management LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at approximately $11,826,000. Two Sigma Advisers LP purchased a new position in shares of Tempus AI in the fourth quarter valued at approximately $625,000. ProShare Advisors LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at approximately $244,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Tempus AI in the fourth quarter valued at approximately $1,034,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.